CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders.
Chloe AnastassiadisIván Martínez-ValbuenaAnna VasilevskayaSimrika ThapaMohsen HadianAlonso Morales-RiveroDaniela Mora-FisherCristina SalvoFoad TaghdiriChristine SatoDanielle MorenoCassandra J AnorKaren MisquittaBlas CoutoDavid F Tang-WaiAnthony E LangSusan H FoxEkaterina A RogaevaGábor G KovácsMaria Carmela TartagliaPublished in: Neurology (2024)
We detected a frequency of αSyn-SAA positivity in CBS and PSP in line with pathologic studies, highlighting the usefulness of SAAs for in vivo detection of otherwise undetectable neuropathologic processes. Our results also suggest that AD status (specifically low Aβ42) and older age at onset may contribute to αSyn-SAA positivity. This opens new perspectives for the stratification of patients in clinical trials.
Keyphrases
- clinical trial
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- physical activity
- prognostic factors
- neoadjuvant chemotherapy
- squamous cell carcinoma
- locally advanced
- middle aged
- open label
- community dwelling
- case control
- loop mediated isothermal amplification
- rectal cancer